Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G protein subunit beta 3 (GNB3) is a regulatory subunit of heterotrimeric G proteins, which are involved in transducing signals from membrane receptors to intracellular effectors in cells. The beta subunit, along with gamma and alpha subunits, is essential for modulating G protein-coupled receptor (GPCR) signaling, GDP/GTP exchange, and interaction with downstream effectors. GNB3 has been widely studied for its C825T polymorphism, which is associated with essential hypertension, obesity, and several signal transduction phenotypes. The gene belongs to the WD-repeat G protein beta family and is expressed in various tissues, where it helps couple extracellular signals to cellular responses. The C825T variant produces a splice variant (GNB3-s), leading to altered signaling capacity that is implicated in disease risk, especially hypertension. No drugs currently directly target GNB3, but its influence on signal transduction may modulate therapeutic responses to molecules acting via GPCRs.
Not directly targeted; GNB3 variants may influence signal transduction response and drug efficacy, especially for agents acting via G protein-coupled receptors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein subunit beta 3 (GNB3).